Corvus Pharmaceuticals, Inc. (CRVS)
Market Cap | 111.34M |
Revenue (ttm) | n/a |
Net Income (ttm) | -24.86M |
Shares Out | 62.55M |
EPS (ttm) | -0.51 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 130,261 |
Open | 1.920 |
Previous Close | 1.850 |
Day's Range | 1.750 - 1.920 |
52-Week Range | 1.050 - 3.160 |
Beta | 1.10 |
Analysts | Buy |
Price Target | 5.75 (+223.03%) |
Earnings Date | Aug 6, 2024 |
About CRVS
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also develop... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 3 analysts, the average rating for CRVS stock is "Buy." The 12-month stock price forecast is $5.75, which is an increase of 223.03% from the latest price.
News
![](https://cdn.snapi.dev/images/v1/a/x/conf12-2454849.jpg)
Corvus Pharmaceuticals to Present at the Jefferies Global Health Conference
BURLINGAME, Calif., May 30, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that Richard A. Miller, M.D., president an...
![](https://cdn.snapi.dev/images/v1/g/n/press19-2413031.jpg)
Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2024 Financial Results
Soquelitinib Phase 1 Randomized Trial in Atopic Dermatitis Enrolling at Multiple Centers; Potential for Early Data Before Year-End 2024
![](https://cdn.snapi.dev/images/v1/a/h/conf13-2407490.jpg)
Corvus Pharmaceuticals to Provide Business Update and First Quarter 2024 Financial Results on May 6, 2024
Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT
![](https://cdn.snapi.dev/images/v1/9/t/press18-2406009.jpg)
Corvus Pharmaceuticals Announces Pricing of $30.6 Million Registered Direct Offering
BURLINGAME, Calif., May 02, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Corvus or the Company) (Nasdaq: CRVS) (GLOBAL NEWSWIRE), a clinical-stage biopharmaceutical company, today announced ...
![](https://cdn.snapi.dev/images/v1/g/a/press17-2364024.jpg)
Corvus Pharmaceuticals Announces Initiation of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis
Atopic dermatitis is the first immune disease indication being studied in the clinic for soquelitinib, the Company's selective ITK inhibitor
![](https://cdn.snapi.dev/images/v1/t/k/press7-2331778.jpg)
Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
Soquelitinib advancing towards initial enrollment for registrational Phase 3 clinical trial for PTCL and randomized Phase 1 clinical trial for atopic dermatitis
![](https://cdn.snapi.dev/images/v1/s/x/conf15-2323052.jpg)
Corvus Pharmaceuticals to Provide Business Update and Fourth Quarter and Full Year 2023 Financial Results on March 19, 2024
Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT
![](https://cdn.snapi.dev/images/v1/z/j/press2-2271346.jpg)
Corvus Pharmaceuticals Presents Soquelitinib Preclinical Data at the Keystone Symposia on Systemic Autoimmune and Autoinflammatory Diseases
Poster presentation unveils Corvus' next-generation ITK inhibitor candidates designed to deliver precise T cell modulation for immunology indications Poster presentation unveils Corvus' next-generatio...
![](https://cdn.snapi.dev/images/v1/n/w/press13-2241331.jpg)
Corvus Pharmaceuticals Announces the Passing of Board Member Edith P. Mitchell
BURLINGAME, Calif., Jan. 23, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, is deeply saddened to announce the passing of Edith P. Mi...
![](https://cdn.snapi.dev/images/v1/h/m/press19-2190201.jpg)
Corvus Pharmaceuticals Presents New Interim Soquelitinib Data from its Phase 1/1b T Cell Lymphoma Trial
Anti-tumor activity and durability of responses data support advancement of soquelitinib (formerly known as CPI-818) into Phase 3 registrational clinical trial and its potential to address the need fo...
![](https://cdn.snapi.dev/images/v1/u/k/press14-2145114.jpg)
Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2023 Financial Results
Protocol finalized for soquelitinib (CPI-818) Phase 3 registrational clinical trial in peripheral T cell lymphoma (PTCL); multiple sites preparing to initiate trial enrollment
![](https://cdn.snapi.dev/images/v1/a/v/conf11-2136268.jpg)
Corvus Pharmaceuticals to Present New Interim Soquelitinib Data from its Phase 1/1b T Cell Lymphoma Trial at the 65th American Society of Hematology (ASH) Annual Meeting & Exposition
BURLINGAME, Calif., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that it will present new interim data fro...
![](https://cdn.snapi.dev/images/v1/i/4/press6-2134855.jpg)
Corvus Pharmaceuticals Announces Publication of Preclinical Data Demonstrating Potential of ITK Inhibition with Soquelitinib as a Novel Approach to T Cell-Mediated Inflammatory and Immune Diseases
Data demonstrated soquelitinib was active in six inflammatory/immune disease models and provides rationale for development in a range of additional Th2- and Th17-mediated diseases
![](https://cdn.snapi.dev/images/v1/b/e/conf4-2131476.jpg)
Corvus Pharmaceuticals to Provide Business Update and Report Third Quarter Financial Results on November 7, 2023
Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT
![](https://cdn.snapi.dev/images/v1/b/j/press14-2052407.jpg)
Corvus Pharmaceuticals Confirms Planned Initiation of Soquelitinib (CPI-818) Phase 3 Registrational Clinical Trial in Peripheral T Cell Lymphoma Following Meeting with FDA
Plans to initiate soquelitinib potentially registrational Phase 3 clinical trial in Q1 2024 Company to host conference call and webcast tomorrow at 8:30 a.m. ET / 5:30 a.m.
![](https://cdn.snapi.dev/images/v1/n/m/press6-2012918.jpg)
Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2023 Financial Results
Interim Phase 1/1b clinical results with soquelitinib and published clinical studies on mechanism of action continue to support potential of ITK inhibition as novel immunotherapy for hematologic and s...
![](https://cdn.snapi.dev/images/v1/s/7/conf20-1998741.jpg)
Corvus Pharmaceuticals to Provide Business Update and Report Second Quarter Financial Results on August 8, 2023
Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT
![](https://cdn.snapi.dev/images/v1/x/4/press5-1961132.jpg)
Corvus Pharmaceuticals Announces Publication of Preclinical Data Demonstrating Potential Novel Approach to Immunotherapy Based on Inhibition of ITK with Soquelitinib (CPI-818)
Data highlights the differentiated mechanism of action of soquelitinib to enhance anti-tumor immune response to hematologic and solid tumors
![](https://cdn.snapi.dev/images/v1/m/r/press5-1952854.jpg)
Corvus Pharmaceuticals Presents New Ciforadenant Preclinical Data at the 2nd JCA-AACR Precision Cancer Medicine International Conference
Preclinical data highlights ciforadenant's mechanism of action and synergy with immune checkpoint inhibitors Enrollment continues in Phase 1b/2 clinical trial evaluating ciforadenant as a potential fi...
![](https://cdn.snapi.dev/images/v1/o/b/press17-1935189.jpg)
Corvus Pharmaceuticals Presents New CPI-818 Interim Data at the International Conference on Malignant Lymphoma
Data supported CPI-818's novel immunotherapy mechanism of action and its potential to provide a platform approach to a broad range of solid and hematological cancers
![](https://cdn.snapi.dev/images/v1/k/j/conf14-1914122.jpg)
Corvus Pharmaceuticals to Present at the Jefferies Healthcare Conference
BURLINGAME, Calif., May 31, 2023 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that Richard A. Miller, M.D., president an...
![](https://cdn.snapi.dev/images/v1/e/9/conf18-1895087.jpg)
Corvus Pharmaceuticals to Present New CPI-818 Data at the International Conference on Malignant Lymphoma
BURLINGAME, Calif., May 17, 2023 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced that it will present new data for CPI-818,...
![](https://cdn.snapi.dev/images/v1/a/1/press1-1877757.jpg)
Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2023 Financial Results
Updated interim results from CPI-818 Phase 1/1b clinical trial continues to support potential of ITK inhibition and the ALC biomarker in T cell lymphoma
![](https://cdn.snapi.dev/images/v1/7/t/conf7-1845766.jpg)
Corvus Pharmaceuticals to Provide Business Update and Report First Quarter 2023 Financial Results on May 8, 2023
Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT
![](https://cdn.snapi.dev/images/v1/m/x/press12-1839510.jpg)
Corvus Pharmaceuticals Presents New CPI-818 Data Demonstrating the Potential of ITK Inhibition as a Treatment for Solid and Hematologic Cancers at the American Association for Cancer Research (AACR) Annual Meeting
Preclinical data supports targeting ITK as a new approach for cancer immunotherapy Novel mechanism of action modulates T cell differentiation and enhances the immune system via Th1 skewing, increased ...